Tianyi Wang, Yanjing Tang, Jiaoyang Cai, Xinyu Wan, Shaoyan Hu, Xiaoxi Lu, Zhiwei Xie, Xiaohong Qiao, Hui Jiang, Jingbo Shao, Fan Yang, Hong Ren, Qing Cao, Juan Qian, Jian Zhang, Kang An, Jianmin Wang, Chengjuan Luo, Huanhuan Liang, Yan Miao, Yani Ma, Xiang Wang, Lixia Ding, Lili Song, Hailong He, Wenhua Shi, Peifang Xiao, Xiaomin Yang, Jing Yang, Wenjie Li, Yiping Zhu, Ningling Wang, Longjun Gu, Qimin Chen, Jingyan Tang, Jun J Yang, Cheng Cheng, Wing Leung, Jing Chen, Jun Lu, Benshang Li, Ching-Hon Pui
PURPOSE: We determined the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia. PATIENTS AND METHODS: This phase II trial enrolled 225 evaluable patients age ≤ 20 years between September 17, 2019, and December 31, 2021. We first conducted a safety run-in stage to determine the recommended dose...
November 8, 2022: Journal of Clinical Oncology